ARTICLE | Clinical News
Dalbavancin regulatory update
January 6, 2014 8:00 AM UTC
On Dec. 23, 2013, Durata said EMA accepted for review an MAA for dalbavancin to treat complicated skin and soft tissue infections (cSSTI) caused by susceptible Gram-positive microorganisms. The compan...